Press Release
View printer-friendly version
Materialise Reports First Quarter 2020 Results
LEUVEN,
Highlights – First Quarter 2020
-
Total revenue decreased 1.8% to 46,245 kEUR for the first quarter of 2020 compared to the 2019 period, despite continued revenue growth in our
Materialise Software and Materialise Medical segments of 5.0% and 15.3%, respectively. -
Total deferred revenues from annual software sales and maintenance fees increased 2,037 kEUR to 29,703 kEUR compared to
December 31, 2019 . - Adjusted EBITDA decreased 38.2% to 3,603 kEUR for the first quarter of 2020 compared to the 2019 period.
-
Net loss for the first quarter of 2020 was (2,853) kEUR, or
(0.05) EUR per diluted share, compared to (304) kEUR, or(0.01) EUR per diluted share, for the 2019 period. -
Total cash was 127,135 kEUR at the end of the quarter; net cash was 2,433 kEUR, an increase of 1,474 kEUR compared to
December 31, 2019 .
Executive Chairman
“Our current view is that, after the crisis, market interest in 3D printing, in general, and in meaningful applications for 3D printing, in particular, should pick up relatively quickly, including as a result of the many 3D printed solutions that have addressed new market needs so expeditiously during the crisis. We believe Materialise will be uniquely positioned to capture some of these opportunities. Accordingly, while we have implemented a variety of health, safety and cost-saving measures, our focus is on maintaining, as much as reasonably possible, our strategic investments in the majority of the research and business development projects currently in process throughout our three segments. Supported by our strong balance sheet, this focus should position us well to further expand our existing business and take advantage of new growth opportunities when current conditions improve.”
First Quarter 2020 Results
Total revenue for the first quarter of 2020 decreased 1.8% to 46,245 kEUR compared to 47,115 kEUR for the first quarter of 2019. Adjusted EBITDA decreased to 3,603 kEUR from 5,827 kEUR. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the first quarter of 2020 was 7.8% compared to 12.4% for the first quarter of 2019.
Revenue from our
Revenue from our Materialise Medical segment increased 15.3% to 15,645 kEUR for the first quarter of 2020 compared to 13,566 kEUR for the same period in 2019. Compared to the first quarter of 2019, revenues from medical devices and services grew 18.2% and revenues from our medical software grew 9.8%. Segment EBITDA increased to 2,455 kEUR compared to 1,773 kEUR while the segment EBITDA margin was 15.7% compared to 13.1% for the first quarter of 2019.
Revenue from our Materialise Manufacturing segment decreased 13.9% to 20,815 kEUR for the first quarter of 2020 from 24,184 kEUR for the first quarter of 2019. Segment EBITDA decreased to 1,118 kEUR from 3,695 kEUR while the segment EBITDA margin was 5.4% compared to 15.3% for the first quarter of 2019.
Gross profit was 24,632 kEUR, or 53.3% of total revenue, for the first quarter of 2020 compared to 25,579 kEUR, or 54.3% of total revenue, for the first quarter of 2019.
Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 3.9% to 26,351 kEUR for the first quarter of 2020 from 25,361 kEUR for the first quarter of 2019.
Net other operating income was 683 kEUR compared to 1,258 kEUR for the first quarter of 2019.
Operating result decreased to (1,037) kEUR from 1,476 kEUR for the first quarter of 2019.
Net financial result was (1,321) kEUR compared to (592) kEUR for the first quarter of 2019. The share in loss of joint venture amounted to (39) kEUR compared to (123) kEUR for the same period in 2019.
The first quarter of 2020 contained income tax expenses of (457) kEUR, compared to (1,065) kEUR in the first quarter of 2019.
As a result of the above, net loss for the first quarter of 2020 was (2,853) kEUR, compared to (304) kEUR for the same period in 2019. Total comprehensive income for the first quarter of 2020, which includes exchange differences on translation of foreign operations, was (6,996) kEUR compared to 284 kEUR for the 2019 period.
At
Cash flow from operating activities for the first quarter of 2020 was 7,273 kEUR compared to 4,081 kEUR for the same period in 2019. Total capital expenditures for the first quarter of 2020 amounted to 3,053 kEUR.
Net shareholders’ equity at
2020 Guidance
Non-IFRS Measures
Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding non-cash stock-based compensation expenses and acquisition-related expenses of business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the company’s day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.
Exchange Rate
This document contains translations of certain euro amounts into
Conference Call and Webcast
Materialise will hold a conference call and simultaneous webcast to discuss its financial results for the first quarter of 2020 on
-
To access the conference call, please dial 844-469-2530 (
U.S. ) or 765-507-2679 (international), passcode 1698319#.
The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com. A webcast of the conference call will be archived on the company's website for one year.
About Materialise
Materialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations, plans, objectives, strategies and prospects, both financial and business, including statements concerning, among other things, , our results of operations, cash needs, capital expenditures, expenses, financial condition, liquidity, prospects, growth and strategies (including how our business, results of operations and financial condition could be impacted by the COVID-19 pandemic and related public health measures, as well as the related actions we are taking in response), and the trends and competition that may affect the markets, industry or us. Such statements are subject to known and unknown uncertainties and risks. When used in this press release, the words “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,” “could,” “might,” “aim,” “should,” and variations of such words or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. These expectations, beliefs and projections are expressed in good faith and the company believes there is a reasonable basis for them. However, the company cannot offer any assurance that our expectations, beliefs and projections will actually be achieved. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. All of the forward-looking statements are subject to risks and uncertainties that may cause the company's most recent actual results to differ materially from our expectations, including risk factors described in the company's most recent annual report on Form 20-F filed with the
The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
Consolidated income statements (Unaudited) |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended
|
|
|
|
|
|
For the three
|
|
|||||||||||||||
In 000 |
|
2020 |
|
|
2020 |
|
|
2019 |
|
|
|
|
|
2020 |
|
|
2019 |
|
||||||
|
|
U.S.$ |
|
|
€ |
|
|
€ |
|
|
|
|
|
€ |
|
|
€ |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Revenue |
|
|
51,069 |
|
|
|
46,245 |
|
|
|
47,155 |
|
|
|
|
|
|
|
46,245 |
|
|
|
47,115 |
|
Cost of sales |
|
|
(23,867) |
|
|
|
(21,613) |
|
|
|
(21,536) |
|
|
|
|
|
|
|
(21,613) |
|
|
|
(21,536) |
|
Gross profit |
|
|
27,201 |
|
|
|
24,632 |
|
|
|
25,579 |
|
|
|
|
|
|
|
24,632 |
|
|
|
25,579 |
|
Gross profit as % of revenue |
|
|
53.3% |
|
|
|
53.3% |
|
|
|
54.3% |
|
|
|
|
|
|
|
53.3% |
|
|
|
54.3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
|
(7,208) |
|
|
|
(6,527) |
|
|
|
(5,686) |
|
|
|
|
|
|
|
(6,527) |
|
|
|
(5,686) |
|
Sales and marketing expenses |
|
|
(13,945) |
|
|
|
(12,627) |
|
|
|
(12,079) |
|
|
|
|
|
|
|
(12,627) |
|
|
|
(12,079) |
|
General and administrative expenses |
|
|
(7,948) |
|
|
|
(7,197) |
|
|
|
(7,596) |
|
|
|
|
|
|
|
(7,197) |
|
|
|
(7,596) |
|
Net other operating income (expenses) |
|
|
754 |
|
|
|
683 |
|
|
|
1,258 |
|
|
|
|
|
|
|
683 |
|
|
|
1,258 |
|
Operating (loss) profit |
|
|
(1,145) |
|
|
|
(1,037) |
|
|
|
1,476 |
|
|
|
|
|
|
|
(1,037) |
|
|
|
1,476 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial expenses |
|
|
(2,011) |
|
|
|
(1,821) |
|
|
|
(1,196) |
|
|
|
|
|
|
|
(1,821) |
|
|
|
(1,196) |
|
Financial income |
|
|
552 |
|
|
|
500 |
|
|
|
604 |
|
|
|
|
|
|
|
500 |
|
|
|
604 |
|
Share in loss of joint venture |
|
|
(43) |
|
|
|
(39) |
|
|
|
(123) |
|
|
|
|
|
|
|
(39) |
|
|
|
(123) |
|
(Loss) profit before taxes |
|
|
(2,646) |
|
|
|
(2,396) |
|
|
|
761 |
|
|
|
|
|
|
|
(2,396) |
|
|
|
761 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes |
|
|
(505) |
|
|
|
(457) |
|
|
|
(1,065) |
|
|
|
|
|
|
|
(457) |
|
|
|
(1,065) |
|
Net (loss) profit for the period |
|
|
(3,151) |
|
|
|
(2,853) |
|
|
|
(304) |
|
|
|
|
|
|
|
(2,853) |
|
|
|
(304) |
|
Net (loss) profit attributable to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The owners of the parent |
|
|
(3,100) |
|
|
|
(2,807) |
|
|
|
(304) |
|
|
|
|
|
|
|
(2,807) |
|
|
|
(304) |
|
Non-controlling interest |
|
|
(51) |
|
|
|
(47) |
|
|
|
– |
|
|
|
|
|
|
|
(47) |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share attributable to owners of the parent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Basic |
|
|
(0.06) |
|
|
|
(0.05) |
|
|
|
(0.01) |
|
|
|
|
|
|
|
(0.05) |
|
|
|
(0.01) |
|
Diluted |
|
|
(0.06) |
|
|
|
(0.05) |
|
|
|
(0.01) |
|
|
|
|
|
|
|
(0.05) |
|
|
|
(0.01) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average basic shares outstanding |
|
|
53,173 |
|
|
|
53,173 |
|
|
|
52,891 |
|
|
|
|
|
|
|
53,173 |
|
|
|
52,891 |
|
Weighted average diluted shares outstanding |
53,173 |
53,173 |
52,891 |
53,173 |
52,891 |
Consolidated statements of comprehensive income (Unaudited) |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended
|
|
|
|
|
|
For the three
|
|
|||||||||||||||
In 000 |
|
2020 |
|
|
2020 |
|
|
2019 |
|
|
|
|
|
2020 |
|
|
2019 |
|
||||||
|
|
U.S.$ |
|
|
€ |
|
|
€ |
|
|
|
|
|
€ |
|
|
€ |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net profit (loss) for the period |
|
|
(3,151) |
|
|
|
(2,853) |
|
|
|
(304) |
|
|
|
|
|
|
|
(2,853) |
|
|
|
(304) |
|
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange difference on translation of foreign operations |
|
|
(4.575) |
|
|
|
(4,143) |
|
|
|
588 |
|
|
|
|
|
|
|
(4,143) |
|
|
|
588 |
|
Other comprehensive income (loss), net of taxes |
|
|
(4,575) |
|
|
|
(4,143) |
|
|
|
588 |
|
|
|
|
|
|
|
(4,143) |
|
|
|
588 |
|
Total comprehensive income (loss) for the year, net of taxes |
|
|
(7,726) |
|
|
|
(6,996) |
|
|
|
284 |
|
|
|
|
|
|
|
(6,996) |
|
|
|
284 |
|
Total comprehensive income (loss) attributable to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The owners of the parent |
|
|
(6,997) |
|
|
|
(6,336) |
|
|
|
284 |
|
|
|
|
|
|
|
(6,336) |
|
|
|
284 |
|
Non-controlling interest |
(729) |
(660) |
– |
(660) |
– |
Consolidated statement of financial position (Unaudited) |
||||||||
|
|
|
|
|
|
|
|
|
|
|
As of March
|
|
|
As of December 31, |
|
||
In 000 |
|
2020 |
|
|
2019 |
|
||
|
|
€ |
|
|
€ |
|
||
Assets |
|
|
|
|
|
|
|
|
|
|
|
||||||
Non-current assets |
|
|
|
|
|
|
|
|
|
|
|
19,424 |
|
|
|
20,174 |
|
Intangible assets |
|
|
26,092 |
|
|
|
27,395 |
|
Property, plant & equipment |
|
|
88,682 |
|
|
|
90,331 |
|
Right-of-Use assets |
|
|
10,057 |
|
|
|
10,586 |
|
Investments in joint ventures |
|
|
- |
|
|
|
39 |
|
Deferred tax assets |
|
|
257 |
|
|
|
192 |
|
Other non-current assets |
|
|
10,053 |
|
|
|
9,391 |
|
Total non-current assets |
|
|
154,565 |
|
|
|
158,108 |
|
|
|
|
||||||
Current assets |
|
|
|
|
|
|
|
|
Inventories |
|
|
12,674 |
|
|
|
12,696 |
|
Trade receivables |
|
|
37,174 |
|
|
|
40,322 |
|
Other current assets |
|
|
10,080 |
|
|
|
9,271 |
|
Cash and cash equivalents |
|
|
127,135 |
|
|
|
128,897 |
|
Total current assets |
|
|
187,063 |
|
|
|
191,186 |
|
Total assets |
341,628 |
349,294 |
|
|
|
|
|
|
|
|
|
|
|
As of March
|
|
|
As of
31, |
|
||
In 000 |
|
2020 |
|
|
2019 |
|
||
|
|
€ |
|
|
€ |
|
||
Equity and liabilities |
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
Share capital |
|
|
3,066 |
|
|
|
3,066 |
|
Share premium |
|
|
138,090 |
|
|
|
138,090 |
|
Consolidated reserves |
|
|
(3,007) |
|
|
|
(195) |
|
Other comprehensive income |
|
|
(4,918) |
|
|
|
(1.394) |
|
Equity attributable to the owners of the parent |
|
|
133,231 |
|
|
|
139,567 |
|
Non-controlling interest |
|
|
2,447 |
|
|
|
3,107 |
|
Total equity |
|
|
135,679 |
|
|
|
142,675 |
|
|
|
|
||||||
Non-current liabilities |
|
|
|
|
|
|
|
|
Loans & borrowings |
|
|
100,999 |
|
|
|
104,673 |
|
Lease liabilities |
|
|
6,510 |
|
|
|
6,427 |
|
Deferred tax liabilities |
|
|
5,906 |
|
|
|
5,747 |
|
Deferred income |
|
|
5,418 |
|
|
|
5,031 |
|
Other non-current liabilities |
|
|
584 |
|
|
|
696 |
|
Total non-current liabilities |
|
|
119,418 |
|
|
|
122,575 |
|
|
|
|
||||||
Current liabilities |
|
|
|
|
|
|
|
|
Loans & borrowings |
|
|
13,821 |
|
|
|
13,389 |
|
Lease liabilities |
|
|
3,372 |
|
|
|
3,449 |
|
Trade payables |
|
|
18,166 |
|
|
|
18,516 |
|
Tax payables |
|
|
3,048 |
|
|
|
3,363 |
|
Deferred income |
|
|
29,471 |
|
|
|
27,641 |
|
Other current liabilities |
|
|
18,653 |
|
|
|
17,686 |
|
Total current liabilities |
|
|
86,531 |
|
|
|
84,044 |
|
|
|
|
||||||
Total equity and liabilities |
341,628 |
349,294 |
Consolidated statement of cash flows (Unaudited) |
||||
|
|
|
|
|
|
|
For the three months ended March
|
||
in 000 |
|
2020 |
|
2019 |
|
|
€ |
|
€ |
Operating activities |
|
|
|
|
Net (loss) profit for the period |
|
(2,853) |
|
(304) |
Non-cash and operational adjustments |
|
|
|
|
Depreciation of property, plant & equipment |
|
3,600 |
|
3,429 |
Amortization of intangible assets |
|
1,115 |
|
1,101 |
Share-based payment expense |
|
(75) |
|
(177) |
Loss (gain) on disposal of property, plant & equipment |
|
16 |
|
51 |
Movement in provisions |
|
(3) |
|
14 |
Movement reserve for bad debt |
|
221 |
|
(136) |
Financial income |
|
(500) |
|
(60) |
Financial expense |
|
1,821 |
|
583 |
Impact of foreign currencies |
|
|
|
83 |
Share in loss of a joint venture (equity method) |
|
39 |
|
124 |
(Deferred) income taxes |
|
454 |
|
1,065 |
Other |
|
147 |
|
35 |
Working capital adjustment & income tax paid |
|
|
|
|
Decrease (increase) in trade receivables and other receivables |
|
1,582 |
|
(2,393) |
Decrease (increase) in inventories |
|
(3) |
|
(1,200) |
Increase (decrease) in trade payables and other payables |
|
2,300 |
|
2,251 |
Income tax paid |
|
(588) |
|
(385) |
Net cash flow from operating activities |
|
7.273 |
|
4,081 |
|
|
|
|
|
|
|
For the three months ended March
|
||
in 000 |
|
2020 |
|
2019 |
|
|
€ |
|
€ |
Investing activities |
|
|
|
|
Purchase of property, plant & equipment |
|
(2,575) |
|
(2,657) |
Purchase of intangible assets |
|
(478) |
|
(575) |
Proceeds from the sale of property, plant & equipment & intangible assets |
|
69 |
|
– |
Convertible loan to third party |
|
(300) |
|
(2,500) |
Investments in joint-ventures |
|
– |
|
– |
Interest received |
|
– |
|
53 |
Net cash flow used in investing activities |
|
(3,284) |
|
(5,679) |
|
|
|
|
|
Financing activities |
|
|
|
|
Proceeds from loans & borrowings |
|
|
|
1,500 |
Repayment of loans & borrowings |
|
(2,585) |
|
(2,543) |
Repayment of finance leases |
|
(1,016) |
|
(1,399) |
Interest paid |
|
(634) |
|
(503) |
Other financial income (expense) |
|
(138) |
|
(110) |
Net cash flow from (used in) financing activities |
|
(4,373) |
|
(3,055) |
|
|
|
|
|
Net increase of cash & cash equivalents |
|
(383) |
|
(4,653) |
Cash & cash equivalents at beginning of the year |
|
128,897 |
|
115,506 |
Exchange rate differences on cash & cash equivalents |
|
(1,379) |
|
199 |
Cash & cash equivalents at end of the year |
|
127,135 |
|
111,052 |
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited) |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months
|
|
|
|
|
|
For the three months
ended |
|
|||||||||||
In 000 |
|
2020 |
|
|
2019 |
|
|
|
|
|
2020 |
|
|
2019 |
|
|||||
|
|
€ |
|
|
€ |
|
|
|
|
|
€ |
|
|
€ |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net profit (loss) for the period |
|
|
(2,853) |
|
|
|
(304) |
|
|
|
|
|
|
|
(2,853) |
|
|
|
(304) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes |
|
|
457 |
|
|
|
1,065 |
|
|
|
|
|
|
|
457 |
|
|
|
1,065 |
|
Financial expenses |
|
|
1,821 |
|
|
|
1,196 |
|
|
|
|
|
|
|
1,821 |
|
|
|
1,196 |
|
Financial income |
|
|
(500 |
) |
|
|
(604 |
) |
|
|
|
|
|
|
(500) |
|
|
|
(604 |
|
Share in loss of joint venture |
|
|
39 |
|
|
|
123 |
|
|
|
|
|
|
|
39 |
|
|
|
123 |
|
Depreciation and amortization |
|
|
4,715 |
|
|
|
4,530 |
|
|
|
|
|
|
|
4,715 |
|
|
|
4,530 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA |
|
|
3,678 |
|
|
|
6,006 |
|
|
|
|
|
|
|
3,678 |
|
|
|
6,006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash stock-based compensation expense (1) |
|
|
(75) |
|
|
|
(177) |
|
|
|
|
|
|
|
(75) |
|
|
|
(177) |
|
Acquisition-related expenses business combinations |
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
– |
|
|
|
– |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTED EBITDA |
|
|
3,603 |
|
|
|
5,829 |
|
|
|
|
|
|
|
3,603 |
|
|
|
5,829 |
|
|
(1) |
Non-cash share-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees. |
Segment P&L (Unaudited) |
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
In 000 |
|
Materialise Software |
|
Materialise Medical |
|
Materialise Manufact- uring |
|
Total segments |
|
Unallocated (1)(2) |
|
Consoli- dated |
|
|
€
|
|
€
|
|
€
|
|
€
|
|
€
|
|
€
|
For the three months ended |
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
9,821 |
|
15,645 |
|
20,815 |
|
46,281 |
|
(36) |
|
46,245 |
Segment adjusted EBITDA |
|
2,645 |
|
2,455 |
|
1,118 |
|
6,218 |
|
(2,615) |
|
3,603 |
|
|
|
|
|
|
|
||||||
Segment adjusted EBITDA % |
|
26.9% |
|
15.7% |
|
5.4% |
|
13.4% |
|
|
|
7.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
9,350 |
|
13,566 |
|
24,184 |
|
47,100 |
|
15 |
|
47,115 |
Segment adjusted EBITDA |
|
2,961 |
|
1,773 |
|
3,695 |
|
8,429 |
|
(2,600) |
|
5,829 |
|
|
|
|
|
|
|
||||||
Segment adjusted EBITDA % |
|
31.7% |
|
13.1% |
|
15.3% |
|
17.9% |
|
|
|
12.4% |
(1) |
Unallocated Revenues consist of occasional one-off sales by our core competencies not allocated to any of our segments. | |
(2) |
Unallocated segment EBITDA consists of corporate research and development, corporate headquarter costs and other operating income (expense), and the added non-cash share-based compensation expenses and acquisition related expenses of business combinations that are included in Adjusted EBITDA. |
Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited) |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months
ended |
|
|
|
|
|
For the three months
ended |
|
|||||||||||
In 000 |
|
2020 |
|
|
2019 |
|
|
|
|
|
2020 |
|
|
2019 |
|
|||||
|
|
€ |
|
|
€ |
|
|
|
|
|
€ |
|
|
€ |
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net profit (loss) for the period |
|
|
(2,853) |
|
|
|
(304) |
|
|
|
|
|
|
|
(2,853) |
|
|
|
(304) |
|
Income taxes |
|
|
457 |
|
|
|
1,065 |
|
|
|
|
|
|
|
457 |
|
|
|
1,065 |
|
Financial cost |
|
|
1,821 |
|
|
|
1,196 |
|
|
|
|
|
|
|
1,821 |
|
|
|
1,196 |
|
Financial income |
|
|
(500) |
|
|
|
(604) |
|
|
|
|
|
|
|
(500) |
|
|
|
(604) |
|
Share in loss of joint venture |
|
|
39 |
|
|
|
123 |
|
|
|
|
|
|
|
39 |
|
|
|
123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit |
|
|
(1,037) |
|
|
|
1,476 |
|
|
|
|
|
|
|
(1,037) |
|
|
|
1,476 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
4,715 |
|
|
|
4,530 |
|
|
|
|
|
|
|
4,715 |
|
|
|
4,530 |
|
Corporate research and development |
|
|
747 |
|
|
|
464 |
|
|
|
|
|
|
|
747 |
|
|
|
464 |
|
Corporate headquarter costs |
|
|
2,368 |
|
|
|
2,565 |
|
|
|
|
|
|
|
2,368 |
|
|
|
2,565 |
|
Other operating (income) expense |
|
|
(575) |
|
|
|
(606) |
|
|
|
|
|
|
|
(575) |
|
|
|
(606) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment EBITDA |
|
|
6,218 |
|
|
|
8,429 |
|
|
|
|
|
|
|
6,218 |
|
|
|
8,429 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005081/en/
Investor Relations
LHA
212.838.3777
hfried@lhai.com
Source: